Compare Moderna, Inc. (MRNA) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Advanced Drainage Systems Inc — how do they compare? Moderna, Inc. trades at $60.51 (market cap $24.18B), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.83B). The key difference: Moderna, Inc. is far larger — about 2.2× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WMS | |
|---|---|---|
Market Cap | $24.18B | $10.83B |
Sector | Health | Industrials |
52-Week High | $81.80 | $175.38 |
52-Week Low | $22.36 | $129.50 |
Enterprise Value | $20.33B | $12.44B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
WMS trades at $140.22, down 1.02% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin. Recent news highlights Q1 2027 revenue growth of 21% year-over-year and a quarterly dividend declaration.
The outlook is mixed: analyst consensus is a Buy with a $185.86 price target, implying upside, but technical weakness and a Zacks Strong Sell rating (June 22, 2026) pose near-term risks. Investment appeal hinges on execution of growth initiatives amid competitive pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
